Pink SheetPublic Citizen is petitioning the US Food and Drug Administration and Drug Enforcement Administration to place gabapentin into schedule V of the Controlled Substances Act due to the drug's potential f
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Pays $35m Up Front To Access Lyci
HBW InsightThe futility of using OTC Drug Facts labels for products indicated to treat conditions more complicated than a cold or heartburn, headaches or allergies was apparent less than 10 years after the forma
HBW InsightBayer AG adds a brand to its US OTC allergy remedy lineup as the Food and Drug Administration adds a first-in-class ingredient to the products it has approved for nonprescription sales with a partial